Tirz

Informal abbreviation widely used for tirzepatide, the dual GLP-1/GIP receptor agonist marketed as Mounjaro (type 2 diabetes) and Zepbound (obesity). Used extensively in online research communities, social media discussions, and healthcare forums. SURMOUNT obesity clinical trials demonstrated average weight reductions of 15–22.5% over 72 weeks depending on dose, driving widespread use of "tirz" as shorthand in clinical and lay discussions about next-generation obesity pharmacotherapy.